Aurobindo Pharma is currently trading higher by 3.78% at Rs 454.15 after the company announced its Q2 result yesterday, 12 November 2019.
The stock traded in the range of Rs 445 and Rs 454.35 so far during the day.
Aurobindo Pharma reported 4.6% increase in consolidated net profit to Rs 639.50 crore on 17.9% rise in revenue from operations to Rs 5600.5 crore in Q2 September 2019 over Q2 September 2018.
EBITDA before forex and other income stood at Rs 1,167.5 crore in Q2 September 2019, up by 13.8% from Rs 1,026 crore in Q2 September 2018. EBITDA margin for the quarter ended on 30 September 2019 stood at 20.8% as against 21.6% during the quarter ended on 30 September 2018.
Commenting on the company's performance, N. Govindarajan, managing director of the company said the company had continued to grow in US and Europe, which are its focused geographies.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's product portfolio comprises of therapeutic/product areas encompassing antibiotics, anti-retroviral, CVS, CNS, gastroenterological, pain management and anti-allergic.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content